A packed MS mar­ket is about to get busier as J&J's pones­i­mod en­ters the fray

When J&J dropped $30 bil­lion in­to an Acte­lion buy­out back in 2017, it hoped the biotech’s pipeline would add some­thing fresh to the mas­sive drug­mak­er’s slow-to-grow port­fo­lio. One of those mid-stage pick­ups, MS can­di­date pones­i­mod, is now ready for show­time in a busy and grow­ing MS mar­ket.

The FDA on Fri­day ap­proved J&J’s S1P1 re­cep­tor mod­u­la­tor pones­i­mod to treat re­laps­ing mul­ti­ple scle­ro­sis, the drug­mak­er said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.